Umbilical Cord Blood Transplantation - MEDICAID - SOUTH CAROLINA

This policy covers umbilical cord blood hematopoietic progenitor cell transplantation (allogeneic cord blood transplantation), including products such as Omidubicel/Omisirge and Regenecyte, for restoring hematopoiesis in disorders affecting the hematopoietic system—primarily hematologic malignancies (e.g., ALL, AML) and inherited or acquired marrow disorders—usually following myeloablative conditioning. Use is limited to unrelated-donor (allogeneic) UCB transplantation in individuals typically aged 12–65, must be given at an approved facility with an appropriate preparative regimen, and often requires corporate transplant department/medical director review; evidence and explicit coverage details are limited in the excerpt.

"Blood or bone marrow cancers (most common indication for hematopoietic stem cell transplantation)."

Sign up to see full coverage criteria, indications, and limitations.